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Heparins are one of the most used class of anticoagulants in daily clinical practice. Despite their widespread
application immune-mediated hypersensitivity reactions to heparins are rare. Among these, the delayed-type
reactions to s.c. injected heparins are well-known usually presenting as circumscribed eczematous plaques at the
injection sites. In contrast, potentially life-threatening systemic immediate-type anaphylactic reactions to heparins
are extremely rare. Recently, some cases of non-allergic anaphylaxis could be attributed to undesirable heparin
contaminants.
A 43-year-old patient developed severe anaphylaxis symptoms within 5–10 minutes after s.c. injection of
enoxaparin. Titrated skin prick testing with wheal and flare responses up to an enoxaparin dilution of 1:10.000
indicated a probable allergic mechanism of the enoxaparin-induced anaphylaxis. The basophil activation test as an
additional in-vitro test method was negative. Furthermore, skin prick testing showed rather broad cross-reactivity
among different heparin preparations tested.
In the presented case, history, symptoms, and results of skin testing strongly suggested an IgE-mediated allergic
hypersensitivity against different heparins. Therefore, as safe alternative anticoagulants the patient could receive
beneath coumarins the hirudins or direct thrombin inhibitors. Because these compounds have a completely
different molecular structure compared with the heparin-polysaccharides.
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Heparins and heparinoids are widely used for preven-
tion and treatment of thromboembolic diseases or
during haemodialysis. Unfractionated heparin (UFH), low-
molecular-weight heparins (LMWHs), fondaparinux, and
the heparinoid danaparoid are indirect anticoagulants
which require the cofactors thrombin, antithrombin, and
factor Xa to exert their activity. UFH is a heterogenous
mixture of glycosaminoglycans (anionic polysaccharides)
that bind to antithrombin via a unique pentasaccharide
sequence and catalyse the inactivation of thrombin, fac-
tor Xa and other clotting enzymes. LMWHs are derived
from UFH by chemical or enzymatic depolymerisation.
They comprise about one third the molecular weight of
UFH with a mean of 4.000 to 5.000 kilo Dalton (kDa).* Correspondence: Anders_D@klinik.uni-wuerzburg.de
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distribution, and reproduction in any mediumCompared with UFH, LMWHs have a greater inhibitory
activity against factor Xa, have superior pharmacokinetic
properties, a longer half-life, and are associated with a sig-
nificant lower risk of heparin-induced thrombocytopenia
(HIT). Fondaparinux, a synthetic pentasaccharide, specific-
ally inhibits factor Xa in an antithrombin-dependent
fashion. For patients with HIT, three parenteral direct
thrombin inhibitors and danaparoid are currently approved
as alternatives to heparin [1].
Considering the widespread use of heparins in daily
medical in- and outpatient practice hypersensitivity reac-
tions to heparins are rare. The delayed-type hypersensiti-
vity (DTH) reactions to s.c. injected heparin preparations
are well-known, usually presenting as itchy erythematous
or eczematous plaques directly around the injection sites.
In spite of some research in this area, the decisive anti-
genic determinants of the heparin molecule have not yet
been identified. A rather characteristic feature of heparin-
DTH is the extensive cross-reactivity among UFH, alled Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Skin prick testing with UFH, LMWHs, heparinoids
and fondaparinux
Drug tested Wheal diameter [mm]
Heparin-sodium 25.000 I.E./ml 3
Nadroparin (Fraxiparin™) 9.500 I.E./ml 4
Dalteparin (Fragmin™) 12.500 I.E./ml 0
Enoxaparin (Clexane™) 10.000 I.E./ml 6 and pseudopodes
Danaparoid (Orgaran™) 1.250 I.E./ml 3
Pentosan polysulfate (Fibrezym™) 100 mg/ml 0
Fondaparinux (Arixtra™) 5 mg/ml 4
Sodium chloride 0.9% solution 0
Histamine 10 mg/ml 5
Reading at 20 minutes. Each test was performed with the undiluted heparin
preparations, i.e. the pure therapeutic heparin solution.
Anders and Trautmann Allergy, Asthma & Clinical Immunology 2013, 9:1 Page 2 of 4
http://www.aacijournal.com/content/9/1/1available LMWHs, and danaparoid. Fondaparinux is also
an anionic polysaccharide and cross-reactivity is likely,
especially if prolonged treatment periods are neces-
sary [2]. Theoretically, heparin-DTH implies the risk of a
generalised exanthema or eczema if heparin is adminis-
tered i.v. Importantly, patients with DTH to s.c. injected
heparins usually tolerate heparin i.v., a phenomenon re-
ferred to as compartment allergy [3].
In contrast to DTH, immediate-type anaphylactic
reactions after heparin administration are extremely
rare. In 2008, several cases of immediate-type reac-
tions after i.v. injected UFH could be clarified as
non-allergic anaphylaxis due to contaminants [4]. In
the patient presented herein, an IgE-mediated allergy
to heparins is suggested by convincing history and
skin testing results.
Case presentation
A 43-year-old male patient presented to our allergy
clinic after a severe anaphylactic episode for further
allergologic work-up. He had simply forgotten oral anti-
coagulation with phenprocoumon and thus alternatively
injected 80 mg enoxaparin s.c. himself at home into the
skin of the abdomen. 5–10 minutes later he was seriously
affected by nausea, sweating, dizziness, erythema, and
intense generalised itching. Blood pressure decreased to
70/40 mm Hg as documented by the emergency physician.
The patient first showed tachycardia with frequencies
up to 140 beats per minute, then he developed an
intermittent junctional escape rhythm with frequen-
cies of 40 beats per minute. He heavily vomited.
Within 15 minutes he was treated by the emergency
physician i.v. with 250 mg prednisolone, 5 mg clemas-
tine, 200 mg cimetidine and 0.5 mg epinephrine. Fol-
lowing emergency treatment he entirely recovered and
the cardiopulmonary surveillance did not show any more
abnormalities. On further questioning his wife affirmed
that there was an impressive wheal directly at the injection
site of enoxaparin at the abdomen in size of the palm of a
hand whereas she described the rest of the skin as blazing
red. Outwards oral anticoagulation with phenprocoumon
was restarted without any overlapping heparin application.
Afterwards he reported that he has also eaten some pea-
nuts just before the anaphylaxis episode.
The personal history comprised a factor V Leiden
mutation in a heterozygous form. Recurrently, he had
experienced thromboembolic events like pulmonary em-
boli and deep venous thromboses. For this reason and
due to additional cardiovascular risk factors like obesity,
hypercholesterolemia, hyperhomocysteinemia and dia-
betes mellitus he previously was advised to continuous
oral anticoagulation with phenprocoumon. Enoxaparin
was applied during total endoprosthesis of the right and
left hip joint 5 and 3 years ago.Laboratory investigations including serum IgE level,
baseline serum tryptase and IgE to whole peanut extract
and the recombinant peanut allergens rAra h 1, 2, 3, 8 and
9 showed no pathological findings. Histamine-controlled
skin prick testing with native peanuts performed on the
volar forearm remained negative. Thereafter, our patient
still consumed peanuts finally ruling out IgE-mediated
peanut allergy as cause of anaphylaxis.
Skin prick testing with the UFH heparin-sodium,
LMWHs (nadroparin, dalteparin, enoxaparin), hepari-
noids (danaparoid, pentosan polysulfate) and fondapari-
nux with reading at 20 minutes revealed the strongest
positive reaction to enoxaparin and additional positive
reactions to heparin-sodium, nadroparin, danaparoid
and fondaparinux (Table 1). We additionally performed
a dilution prick test series with enoxaparin including
1:10, 1:100, 1:1.000, 1:10.000 and 1:100.000 dilutions
(Table 2). Even with the 1:10.000 dilution of enoxaparin,
corresponding to 100 ppm, a positive skin test reaction
was provoked. Therefore, an IgE-mediated hypersensitivity
to enoxaparin was strongly suggested. A basophil activa-
tion test (BAT) with heparin-sodium, pentosan polysul-
fate, danaparoid, fondaparinux, dalteparin, enoxaparin and
nadroparin failed to reveal any positive results.
Conclusions
Up to now, immediate-type hypersensitivity reactions
to heparins were published very rarely. In the litera-
ture we found 9 documented cases of immediate-type
hypersensitivity reactions to heparins (Table 3). Unfortu-
nately, a sufficient allergological work-up suggesting
IgE-mediated allergic hypersensitivity was performed
only in 5 of these cases.
The allergological work-up of immediate-type hyper-
sensitivity reactions to heparins rely on skin prick
and intradermal heparin testing with readings after 15
to 20 minutes. Specificity of heparin skin testing seems to
be high if clearly non-irritating heparin concentrations
Table 2 Skin prick testing dilution series with enoxaparin
10.000 I.E./ml in sodium chloride 0.9% solution
Drug tested Wheal diameter [mm]
Enoxaparin (Clexane™) 1:10 (10%) 6
Enoxaparin (Clexane™) 1:100 (1%) 5
Enoxaparin (Clexane™) 1:1.000 (0,1%) 5
Enoxaparin (Clexane™) 1:10.000 (100 ppm) 3
Enoxaparin (Clexane™) 1:100.000 (10 ppm) 0
Sodium chloride 0.9% solution 0
Histamine 10 mg/ml 7
Reading at 20 minutes. ppm, parts per million.
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is largely unknown. Generally, lower heparin concentra-
tions (i.e. higher dilutions) increase the specificity but may
decrease the sensitivity of testing. Therefore, as a first
screening concentration for heparin hypersensitivity it is
recommended to use the undiluted therapeutic heparin
solutions for prick testing and a 1:10 dilution for intrader-
mal testing, respectively [2].
Using this approach, i.e. undiluted therapeutic heparin
concentrations for prick testing and a 1:10 dilution for
intradermal testing, immediate-type test reactions may be
observed in up to 10% of cases. These reactions should
not be naively interpreted as proof of an IgE-mediated
allergy because they could be caused by an unspecific
heparin-induced histamine liberation. These falsely posi-
tive reactions have to be discriminated from extremely
rare immediate-type allergic reactions by more extensive
skin testing using a further series of dilutions (1:100,
1:1.000, 1:10.000). In true allergic reactions these lower
concentrations should still yield positive results.Table 3 Published cases of immediate-type hypersensitivity r
No. Age
(years)
Sex Causative
heparin
Clinical symptom
1 36 m Porcine heparin Blood pressure decrease, airw
heart fibrillation
2 30 f Dalteparin Urticaria, nausea, dyspnea, s
3 52 m Heparin Hypotension, tachycardia, loss o
4 42 f Nadroparin Generalised urticaria, angioedema, h
5 18 f Enoxaparin Erythematous infiltrated plaqu
6 27 f Enoxaparin Erythematous infiltrated plaques, an
sweating
7 59 f Dalteparin Blood pressure decrease, frequent a
8 52 f Reviparin Dyspnea, cough, whe
9 67 f Heparin Cardiac and respirator
f = female; m = male; SPT = skin prick test; IDT = intradermal test; n.d. = not done.Accordingly, the presented patient demonstrated positive
prick test results up to a 1:10.000 dilution of enoxaparin
suggesting IgE-mediated allergy. The enoxaparin prepar-
ation used for skin testing was composed of enoxaparin
and aqua without further additives. Further, the observed
cross-reactivity throughout a panel of heparin preparations
from different manufacturers tested ruled out a causal role
of contaminants or preservatives added to some products,
such as sodium metabisulfite, benzyl alcohol, or chlorocre-
sol. BAT was proposed as a complementary method
for in-vitro diagnosis of heparin allergy [5]. But until
now, the results of these authors could not be con-
firmed by further published data. Moreover, we and
other groups with experience in the field of heparin
allergy repeatedly failed to detect heparin sensitization
by BAT.
Harr et al. diagnosed IgE-mediated allergy to s.c. injected
dalteparin by positive skin prick and intradermal tests
in a patient with generalised urticaria accompanied by
nausea and mild dyspnea. Surprisingly, skin test-negative
UFH was tolerated in an i.v. challenge test [6]. Van Zuuren
reported of a patient with local urticarial reactions at the
injection sites of nadroparin, once followed by generalised
urticaria, angioedema and collapse. They reported cross-
reactivity with skin-test negative enoxaparin because in a
subcutaneous challenge test generalised urticaria deve-
loped [7]. Berkun and colleagues referred to a patient with
heparin-induced recurrent anaphylaxis during haemodi-
alysis with hypotension and loss of consciousness con-
firmed by positive intradermal skin testing with UFH and
LMWHs. One hour after a heparin-induced anaphylactic
episode an elevated serum tryptase level was measured by
enzyme-linked immunosorbent assay which returned to
normal within 24 hours [8]. Merely historically, allergiceactions to heparins
s Skin test
(causative heparin)
BAT
(causative heparin)
Ref.
ay stoppage, SPT (titrated)
positive
n.d. [9]
wollen hands SPT positive IDT
(1:100) positive
n.d. [6]
f consciousness SPT negative IDT
(undiluted) positive
n.d. [8]
ypotension, collapse SPT positive n.d. [7]
es, angioedema SPT negative, IDT
(diluted?) positive
positive [5]
gioedema, dizziness, SPT negative, IDT
negative
negative [5]
rrhythmias, dyspnea n.d. negative [11]
ezing n.d. n.d. [12]
y arrest n.d. n.d. [13]
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protein contaminants of animal origin during suboptimal
production processes, namely with porcine gut-derived
heparin preparations [9].
Non-allergic heparin-associated anaphylaxis may be
caused by direct histamine release from mast cells and
basophils by nonspecific binding of contaminants or indi-
rectly by complement/kinin activation. In 2008, oversul-
fated chondroitin sulfate and dermatan sulfate could be
proven as contaminants of heparin in a series of patients
with anaphylactic reactions. Oversulfated chondroitin sul-
fate activates the kallikrein-kinin system with generation
of bradykinin and activation of the potent anaphylatoxins
C3a and C5a both leading to anaphylaxis symptoms [4].
In case of therapeutic necessity for immediate anticoa-
gulation in our patient strict avoidance of all heparins is
mandatory. Alternatively, he could receive hirudins or
direct thrombin inhibitors both exhibiting a complete
different molecular structure compared with the heparin-
polysaccharides. Argatroban as a competitive inhibitor of
thrombin is a small molecule with a molecular weight of
500 kDa. It is administered as continuous i.v. infusion
resulting in a plasma half-life of 45 minutes, which could
be monitored by the thromboplastin time. It is licensed
for treatment and prevention of thrombosis associated to
HIT and for anticoagulation during percutaneous coron-
ary interventions when heparin is contraindicated [1].
Dabigatran is an orally taken direct thrombin inhibitor
approved for prophylaxis of deep vein thrombosis after
total hip and total knee arthroplasty. Recently, the ap-
proval was expanded for the prevention of stroke in
patients with atrial fibrillation [10].
Here we reported an extremely rare case of heparin-
induced anaphylaxis assured by skin prick testing up to im-
pressively very high heparin dilutions. Additionally, rather
broad cross-reactivity between available polysaccharide-
anticoagulants, such as UFH, LMWHs and heparinoids,
was observed. In such a situation beneath hirudins the
recently approved direct thrombin inhibitors argatroban
or dagibatran are potential alternatives because of their
completely different chemical structure.
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